9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients

Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients

Estimated reading time: < 1 min

Condition: MALIGNANT PLEURAL MESOTHELIOMA

Estimated Enrollment: 121

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Evaluate the expression and allelic variants of a panel of candidate genes involved in the resistance to drugs, the genome wide copy number changes in patients treated with drugs combination in the first line,  Evaluate retrospectively the correlation between gene expression and polymorphisms in candidate genes and array-CGH data, immunohistochemistry data, and clinical data.,  ,

Interventions: ,

Phase:

Study Type: Observational

Study Design: Observational Model: Cohort, Time Perspective: Retrospective, ,

Primary Completion Date: December 2011

Completion Date: December 2011

Last  Posted Date: December 2, 2014

Location: Istituto Clinico Humanitas, Rozzano, Milano, Italy

Website Link: https://ClinicalTrials.gov/show/NCT00867711

Was this article helpful?
Dislike 0